experiment Weight loss drugs An early stage 1A/2B trial has been shown to help people lose almost 25% of their weight.
Developed by Novo Nordisk, Amycretin works by replicating amylin, which regulates appetite and creates a sense of fulfillment, as well as Glucagon-like peptide 1 (GLP-1), the same hormone used in Ozempic and Wegovy. Insulin secretion.
“Amuletin is the first treatment to utilize two different biological pathways stimulated by amylin and GLP-1 in a single molecule,” Martin Holst Lange, executive vice president and head of development at Novo Nordisk, said in a statement previously sent to Fox News Digital.
A simple change in grandfather reversed the prediabetic diagnosis that left him “pettish”
In a study involving 125 overweight or obese adults, participants received Weekly Injections According to a press release from Novo Nordisk, the weight was reduced compared to those who took the Amycretin placebo.
With each release, the highest dose (up to 60 mg) was lost at 24.3% (up to 24.3%) at pounds up to 24.3% after 36 weeks.
Previous Phase 1 trials of the oral (PIL) version of Amycretin showed that the treatment was “safe and acceptable” and “weight was observed” compared to placebo, the company said.
I took the pill once a day 10% weight lossand those who doubled the dose lost 13%.
Your DNA may be stopping you from losing weight, new research suggests
Another advantage the researchers highlighted is that people taking amuletin appear to not be hitting a “weight loss plateau” and continue to flush the pound as long as they take it.
“The lack of weight loss plateau indicates the possibility of achieving even more weight loss. Extended treatment“Agnes Gasoirek, a senior clinical pharmacology expert at Novo Nordisk, writes in his Phase 1 study results.
Novo Nordisk released its latest survey results at the American Diabetes Association in Chicago on June 22nd. They were also featured in the medical journal Lancet.
“We are pleased with the promising results of Amycretin and the feedback from regulators, and are excited to move both the subcutaneous and oral versions of this molecule into phase 3 development for weight management.”
“These results reflect a robust pipeline of obesity; [and] It focuses on advances in scientific innovation and expanding the range of options available to patients and healthcare professionals. ”
Like other GLP-1, the most common side effects of amuletin are Gastrointestinal symptoms – Mainly nausea, vomiting, and decreased appetite.
The severity adverse events were “mild to moderate,” according to the researchers. More frequent administration resulted in greater side effects.
It is important to closely monitor these side effects, experts advise that GI issues are common Obese patients.
“The outcomes of initial weight loss are certainly encouraged, but further research is needed to ensure that the therapeutic benefits always outweigh the potential risks, especially in long-term management.” Bariatric surgery He previously spoke to Fox News Digital on the NYU Langone Weight Management program.
Click here to sign up for our health newsletter
While GLP-1-based drugs containing this new experimental drug could show promising results, Renfield, who was not involved in the study, emphasized that it was “not a treatment for obesity.”
“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” she said at the time.
Visit us for more health articles www.foxnews.com/health
“While pharmacological treatments can play an important role in managing the condition, they are often the most effective. Other interventions. ”
Next, Novo Nordisk plans to prepare for a third-stage trial of the drug in oral and injectable forms for the management of obesity.
